SAN FRANCISCO — I’ve been ducking in and out of breakout sessions at the J.P. Morgan Healthcare Conference. Here’s what I’ve heard and learned so far:
The Celgene (CELG) era at JPM fizzled out without much fanfare. Bristol-Myers Squibb and Celgene shared the stage early Monday morning for a fireside chat, but Bristol CEO Dr. Giovanni Caforio did most of the talking. As you’d expect, he’s extremely bullish about the outlook for the combined companies. Caforio filled his biopharma buzzword bingo card.